NEW YORK, April 2 - Lion Bioscience has licensed its SRS bioinformatics platform to Incyte Genomics for three years, the German company said on Tuesday.

Financial terms of the deal were not disclosed, but Lion said it expects to pocket annual license fees and royalties from Incyte as well as from those Incyte customers that use the SRS-based software platform.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.